BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11319229)

  • 41. Enhanced fibrinolysis by proteolysed coagulation factor Xa.
    Talbot K; Meixner SC; Pryzdial EL
    Biochim Biophys Acta; 2010 Apr; 1804(4):723-30. PubMed ID: 19931652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the Ca2+-binding sites of annexin II tetramer.
    Filipenko NR; Kang HM; Waisman DM
    J Biol Chem; 2000 Dec; 275(49):38877-84. PubMed ID: 10980196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Annexin II: a mediator of the plasmin/plasminogen activator system.
    Hajjar KA; Krishnan S
    Trends Cardiovasc Med; 1999 Jul; 9(5):128-38. PubMed ID: 10639727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.
    Suenson E; Lützen O; Thorsen S
    Eur J Biochem; 1984 May; 140(3):513-22. PubMed ID: 6233145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The fibrinolytic system in man.
    Collen D; Lijnen HR
    Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly-L-histidine downregulates fibrinolysis.
    Chu AJ; Mathews ST
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):627-32. PubMed ID: 14517486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inherent fibrin fiber tension propels mechanisms of network clearance during fibrinolysis.
    Cone SJ; Fuquay AT; Litofsky JM; Dement TC; Carolan CA; Hudson NE
    Acta Biomater; 2020 Apr; 107():164-177. PubMed ID: 32105833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interactions of heparin and a covalently-linked antithrombin-heparin complex with components of the fibrinolytic system.
    Chander A; Atkinson HM; Stevic I; Berry LR; Kim PY; Chan AK
    Thromb Haemost; 2013 Dec; 110(6):1180-8. PubMed ID: 24048327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The annexin A2 system and vascular homeostasis.
    Flood EC; Hajjar KA
    Vascul Pharmacol; 2011; 54(3-6):59-67. PubMed ID: 21440088
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding.
    Bellagamba C; Hubaishy I; Bjorge JD; Fitzpatrick SL; Fujita DJ; Waisman DM
    J Biol Chem; 1997 Feb; 272(6):3195-9. PubMed ID: 9013554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Physical determinants of fibrinolysis in single fibrin fibers.
    Bucay I; O'Brien ET; Wulfe SD; Superfine R; Wolberg AS; Falvo MR; Hudson NE
    PLoS One; 2015; 10(2):e0116350. PubMed ID: 25714359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urokinase-induced fibrin clot lysis and its inhibition by plasma.
    Carlin G
    Ups J Med Sci; 1980; 85(1):29-33. PubMed ID: 6446181
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteolytic modulation of factor Xa-antithrombin complex enhances fibrinolysis in plasma.
    Talbot K; Meixner SC; Pryzdial EL
    Biochim Biophys Acta; 2013 Jun; 1834(6):989-95. PubMed ID: 23416531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Regulation of fibrinolysis by S100A10 in vivo.
    Surette AP; Madureira PA; Phipps KD; Miller VA; Svenningsson P; Waisman DM
    Blood; 2011 Sep; 118(11):3172-81. PubMed ID: 21768297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of fibrin degradation products on fibrinolytic process.
    Yatsenko TA; Rybachuk VM; Yusova OI; Kharchenko SM; Grinenko TV
    Ukr Biochem J; 2016; 88(2):16-24. PubMed ID: 29227597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin.
    Bok RA; Mangel WF
    Biochemistry; 1985 Jun; 24(13):3279-86. PubMed ID: 3161540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
    Schneider M; Brufatto N; Neill E; Nesheim M
    J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
    Sharma MR; Rothman V; Tuszynski GP; Sharma MC
    Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.